Ostarine, ligandrol, and testolone (RAD-140) are the three compounds most people mean when they say 'SARMs' in a muscle-building context. All three are androgen receptor agonists, all three are unapproved research chemicals, and all three suppress natural testosterone to some degree. They differ mainly in how much human data exists, how potent and suppressive they are, and what the safety signals look like. This guide compares them on evidence rather than reputation.
A note that applies to all three: the doses studied in trials are generally lower than what people take recreationally, so even the best data understates real-world exposure. And because these are grey-market products, mislabelling and contamination mean the compound in a given bottle may not match the label at all. Treat every comparison below as 'assuming you actually have the compound named'.
Ostarine (enobosarm, MK-2866)
Ostarine has by far the most human data of the three. It ran through multiple phase 2 trials for muscle wasting in cancer and other conditions, where at 1 to 3 mg per day it produced measurable gains in lean body mass and some improvement in physical function versus placebo. It is the mildest and best-characterised of the trio.
- Evidence: strongest of the three; real phase 2 trials with lean-mass endpoints.
- Suppression: present but milder than ligandrol at comparable relative doses; still measurable, and greater at recreational doses.
- Safety signals: relatively better-behaved in trials, though HDL cholesterol reductions are common and some liver enzyme changes have been reported.
- Realistic fit: the entry-level muscle SARM, favoured where people want a modest anabolic effect with the most human data behind it.
Ligandrol (LGD-4033)
Ligandrol is more potent than ostarine per milligram and has one well-known phase 1 study in healthy young men. Over 21 days it increased lean mass and clearly suppressed testosterone, free testosterone, SHBG, and FSH in a dose-dependent way. So there is genuine human evidence, but it is a single short study in healthy people plus some patient data, far less than ostarine.
- Evidence: one solid phase 1 study in healthy men plus limited patient data; moderate.
- Suppression: clearly demonstrated and dose-dependent; more suppressive than ostarine.
- Safety signals: lipid changes reported; short study window means longer-term effects are unknown.
- Realistic fit: chosen when people want a stronger anabolic effect than ostarine and accept more suppression; recovery support becomes more relevant.
Testolone (RAD-140)
RAD-140 is the most potent of the three and, paradoxically, the least studied in humans. Its clinical exposure comes mainly from an early breast-cancer program rather than dosing trials in healthy people, so there is essentially no controlled data on how it affects body composition or the hormone axis at the doses users take. What does exist in the literature is a cluster of case reports of drug-induced liver injury associated with products sold as RAD-140, some severe. Whether that reflects the molecule itself or contaminated products is not always clear, which is exactly the problem with an unregulated market.
- Evidence: weakest of the three in healthy humans; largely case reports and preclinical work.
- Suppression: expected to be strong given its potency; user bloodwork is consistent with heavy suppression, but controlled data is lacking.
- Safety signals: multiple published case reports of liver injury; this is the most notable red flag of the three.
- Realistic fit: the most aggressive option and the one with the least human safety characterisation, hardest to justify on an evidence basis.
Side-by-side summary
- Human evidence: ostarine > ligandrol > testolone.
- Potency: testolone > ligandrol > ostarine.
- Suppression (roughly tracks potency): testolone > ligandrol > ostarine.
- Most concerning documented safety signal: testolone (liver-injury case reports).
- Best-characterised, mildest: ostarine.
What the comparison cannot tell you
Even this ranking is built on thin ground. There are no head-to-head human trials comparing the three. There are no long-term outcome data for any of them in healthy lifters. Recreational doses exceed studied doses, and product quality is unreliable. So the sensible reading is relative, not absolute: ostarine is the best-evidenced and mildest, testolone the least-evidenced and the one with the clearest safety flag, and ligandrol sits in between. None of them has the long-term human safety record that would let anyone call it well understood.
Bottom line
If you rank these three purely by weight of human evidence and by the presence of alarming case reports, ostarine comes out ahead as the mildest and best-studied, testolone comes out worst on both counts, and ligandrol lands in the middle with one decent short study and clear suppression. But 'best of three under-studied drugs' is a low bar: all are unapproved, all are suppressive, all lack long-term human data, and all are subject to grey-market mislabelling. This is reference information, not medical advice.